枸橼酸伏维西利胶囊 | China Drugs ListFovinaciclib citrate capsules | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 锦州奥鸿药业有限责任公司Jinzhou Ahon Pharmaceutical Co., Ltd.
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 用于激素受体（HR）阳性、人表皮生长因子受体2（HER2）阴性的局部晚期或转移性乳腺癌成人患者：①与芳香化酶抑制剂联合，作为初始内分泌治疗；②与氟维司群联合，用于既往接受内分泌治疗后出现疾病进展的患者。For adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer: (1) with an aromatase inhibitor as initial endocrine therapy; or (2) with fulvestrant after progression on previous endocrine therapy.
- 适应症来源与口径
- 来源日期： 2026-04-27, 2026-10-23. 生产商面向中国大陆的药品说明书。 证据核查日期：2026年10月23日。Source date(s): 2026-04-27, 2026-10-23. Manufacturer prescribing information for Mainland China. Evidence review: 23 October 2026.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限联合氟维司群用于既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮生长因子2(HER2)阴性的复发或转移性成年乳腺癌患者。Restricted to use with fulvestrant for adults with HR-positive, HER2-negative recurrent or metastatic breast cancer that has progressed after previous endocrine therapy.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
来源
- https://www.cde.org.cn/main/news/viewInfoCommon/b93aba16ec47467317057dca4aac8437
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.henlius.com/upload/202606/09/%E6%9E%B8%E6%A9%BC%E9%85%B8%E4%BC%8F%E7%BB%B4%E8%A5%BF%E5%88%A9%E8%83%B6%E5%9B%8A-%E8%AF%B4%E6%98%8E%E4%B9%A6.pdf